サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1373634

抗血小板薬の世界市場規模、シェア、産業動向分析レポート：投与経路別、薬剤クラス別、流通チャネル別、地域別展望と予測、2023年～2030年

Global Antiplatelet Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drug Class, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030
出版日: | 発行: KBV Research | ページ情報: 英文 312 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗血小板薬の世界市場規模、シェア、産業動向分析レポート：投与経路別、薬剤クラス別、流通チャネル別、地域別展望と予測、2023年～2030年
出版日: 2023年09月30日
発行: KBV Research
ページ情報: 英文 312 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗血小板薬市場規模は、予測期間中にCAGR 4.7％で成長し、2030年には51億米ドルに達すると予測されます。2022年の市場規模は4億3,040万単位で、成長率は3.4%（2019～2022年）です。

しかし、抗血小板療法を含むヘルスケアや医薬品へのアクセスは、高所得国と低所得国で大きく異なります。ヘルスケアのインフラやリソースの格差は、十分なサービスを受けていない地域における必須医薬品へのアクセスを制限する可能性があります。農村部や遠隔地の患者は、抗血小板薬が入手可能なヘルスケア施設や薬局へのアクセスに課題を抱えています。地理的な障壁は治療の遅れにつながります。抗血小板薬を含む特定の薬剤の定期的な供給不足は、患者の治療に支障をきたし、必要不可欠な薬剤の入手を困難にします。コストと入手しやすさの課題は、市場に影響を与える重要な障壁であり、患者の必須医薬品へのアクセスに影響を与える可能性があります。

さらに、多くの国のヘルスケアシステムは、COVID-19がもたらす当面の脅威に対処することに大きな重点を置いていました。この優先順位の変化は、心血管疾患のような慢性疾患の管理を含む、日常的なヘルスケアサービスの中断につながっています。その結果、抗血小板療法や定期検診を受けるのが遅れた患者もいた。パンデミックの間、処方パターンに変化があっています。一部のヘルスケアプロバイダーは、来院や検査モニタリングの必要性を減らすために治療計画を変更しました。その結果、抗血小板薬の選択や投与量の調整が変更されました。さらに、パンデミックの間、非経口抗血小板薬の需要が増加したことも、市場の成長にプラスの影響を与えました。

投与経路別の展望

投与経路に基づき、市場は経口剤と注射剤に分類されます。2022年には、経口剤が市場で最大の売上シェアを占めました。アスピリンは、経口抗血小板薬として最も古く、最も広く使用されている薬剤の一つです。シクロオキシゲナーゼ-1（COX-1）を不可逆的に阻害することで作用し、血小板凝集物質であるトロンボキサンA2（TXA2）の産生を低下させる。アスピリンは、心臓発作や脳卒中などの心血管イベントを予防するために低用量で使用されることが多いです。経口抗血小板薬は抗血小板市場の重要な構成要素です。これらの薬剤は、血小板凝集を阻害し、血栓形成のリスクを低減し、様々な心血管系疾患を予防または管理するために経口投与されます。

薬剤クラス別展望

薬剤クラス別では、アデノシン二リン酸（ADP）受容体阻害薬、不可逆的阻害薬シクロオキシゲナーゼ、その他に分類されます。2022年の市場では、非可逆的COX阻害薬シクロオキシゲナーゼ・セグメントがかなりの収益シェアを占めています。アスピリンのような非可逆的COX阻害薬は、ADP受容体阻害薬（クロピドグレルのような）と組み合わせて二重抗血小板療法（DAPT）を行うことが多いです。DAPTは、冠動脈ステント留置後や急性冠症候群（ACS）患者に一般的に処方され、血栓形成を予防して心血管イベントのリスクを低下させる。

流通チャネルの展望

流通チャネル別に見ると、市場は病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分けられます。ドラッグストア・小売薬局部門が2022年の最大売上シェアで市場を独占しました。地域社会のドラッグストアや小売薬局は、市販のアスピリンやクロピドグレル、チカグレロルなどの処方薬を含む幅広い抗血小板薬を患者が容易に入手できるようにしています。このような利用しやすさの向上は、急性および慢性疾患のいずれにおいても極めて重要です。ドラッグストアや小売薬局の拡大は、患者のアクセスを向上させ、服薬の安全性、教育、アドヒアランスに貢献しています。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が最も高い収益シェアを獲得して市場をリードしました。北米は、脳卒中、冠動脈疾患、末梢動脈疾患などの心血管疾患の有病率が高いです。これらの疾患では、心臓発作や脳卒中などの血栓性イベントのリスクを低減するために抗血小板療法が必要となることが多いです。北米では、アスピリン、クロピドグレル（プラビックス）、チカグレロル（ブリリンタ）、プラスグレル（エフィエント）など、幅広い抗血小板薬が販売されています。これらの薬剤は急性冠症候群、ステント留置後、二次予防など様々な適応で使用されています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場の概要

  • 主なハイライト

第3章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因
  • ポーターのファイブフォース分析

第4章 世界の抗血小板市場：投与経路別

  • 世界の口腔市場：地域別
  • 世界の注射剤市場：地域別

第5章 世界の抗血小板市場：薬剤クラス別

  • 世界のアデノシン二リン酸（ADP）受容体阻害剤市場：地域別
  • 世界の不可逆的阻害剤シクロオキシゲナーゼ市場：地域別
  • 世界のその他の市場：地域別

第6章 世界の抗血小板市場：流通チャネル別

  • 世界のドラッグストアおよび小売薬局市場：地域別
  • 世界の病院薬局市場：地域別
  • 世界のオンラインプロバイダー市場：地域別

第7章 世界の抗血小板市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第8章 企業プロファイル

  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Eli Lilly And Company
  • Otsuka Pharmaceutical Co, Ltd.
  • Sanofi SA
  • Lupin Limited
  • Chiesi Farmaceutici Sp.A

第9章 抗血小板市場の勝利が不可欠

図表

LIST OF TABLES

  • TABLE 1 Global Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 2 Global Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 3 Global Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 4 Global Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 5 Global Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 6 Global Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 7 Global Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 8 Global Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 9 Global Oral Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Oral Market by Region, 2023 - 2030, USD Million
  • TABLE 11 Global Oral (strip of 10) Market by Region, 2019 - 2022, Million Units
  • TABLE 12 Global Oral (strip of 10) Market by Region, 2023 - 2030, Million Units
  • TABLE 13 Global Injectable Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global Injectable Market by Region, 2023 - 2030, USD Million
  • TABLE 15 Global Injectable Market by Region, 2019 - 2022, Million Units
  • TABLE 16 Global Injectable Market by Region, 2023 - 2030, Million Units
  • TABLE 17 Global Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 18 Global Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 19 Global Adenosine diphosphate (ADP) Receptor Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Adenosine diphosphate (ADP) Receptor Inhibitors Market by Region, 2023 - 2030, USD Million
  • TABLE 21 Global Irreversible Inhibitors Cyclooxygenase Market by Region, 2019 - 2022, USD Million
  • TABLE 22 Global Irreversible Inhibitors Cyclooxygenase Market by Region, 2023 - 2030, USD Million
  • TABLE 23 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 25 Global Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 26 Global Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 27 Global Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 28 Global Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 29 Global Drug store & Retail Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 30 Global Drug store & Retail Pharmacies Market by Region, 2023 - 2030, USD Million
  • TABLE 31 Global Drug store & Retail Pharmacies Market by Region, 2019 - 2022, Million Units
  • TABLE 32 Global Drug store & Retail Pharmacies Market by Region, 2023 - 2030, Million Units
  • TABLE 33 Global Hospital Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 34 Global Hospital Pharmacies Market by Region, 2023 - 2030, USD Million
  • TABLE 35 Global Hospital Pharmacies Market by Region, 2019 - 2022, Million Units
  • TABLE 36 Global Hospital Pharmacies Market by Region, 2023 - 2030, Million Units
  • TABLE 37 Global Online Providers Market by Region, 2019 - 2022, USD Million
  • TABLE 38 Global Online Providers Market by Region, 2023 - 2030, USD Million
  • TABLE 39 Global Online Providers Market by Region, 2019 - 2022, Million Units
  • TABLE 40 Global Online Providers Market by Region, 2023 - 2030, Million Units
  • TABLE 41 Global Antiplatelet Market by Region, 2019 - 2022, USD Million
  • TABLE 42 Global Antiplatelet Market by Region, 2023 - 2030, USD Million
  • TABLE 43 Global Antiplatelet Market by Region, 2019 - 2022, Million Units
  • TABLE 44 Global Antiplatelet Market by Region, 2023 - 2030, Million Units
  • TABLE 45 North America Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 46 North America Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 47 North America Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 48 North America Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 49 North America Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 50 North America Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 51 North America Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 52 North America Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 53 North America Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 54 North America Oral Market by Country, 2023 - 2030, USD Million
  • TABLE 55 North America Oral (strip of 10) Market by Country, 2019 - 2022, Million Units
  • TABLE 56 North America Oral (strip of 10) Market by Country, 2023 - 2030, Million Units
  • TABLE 57 North America Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 58 North America Injectable Market by Country, 2023 - 2030, USD Million
  • TABLE 59 North America Injectable Market by Country, 2019 - 2022, Million Units
  • TABLE 60 North America Injectable Market by Country, 2023 - 2030, Million Units
  • TABLE 61 North America Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 62 North America Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 63 North America Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 64 North America Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 65 North America Irreversible Inhibitors Cyclooxygenase Market by Country, 2019 - 2022, USD Million
  • TABLE 66 North America Irreversible Inhibitors Cyclooxygenase Market by Country, 2023 - 2030, USD Million
  • TABLE 67 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 68 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 69 North America Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 70 North America Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 71 North America Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 72 North America Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 73 North America Drug store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 74 North America Drug store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 75 North America Drug store & Retail Pharmacies Market by Country, 2019 - 2022, Million Units
  • TABLE 76 North America Drug store & Retail Pharmacies Market by Country, 2023 - 2030, Million Units
  • TABLE 77 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 78 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 79 North America Hospital Pharmacies Market by Country, 2019 - 2022, Million Units
  • TABLE 80 North America Hospital Pharmacies Market by Country, 2023 - 2030, Million Units
  • TABLE 81 North America Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 82 North America Online Providers Market by Country, 2023 - 2030, USD Million
  • TABLE 83 North America Online Providers Market by Country, 2019 - 2022, Million Units
  • TABLE 84 North America Online Providers Market by Country, 2023 - 2030, Million Units
  • TABLE 85 North America Antiplatelet Market by Country, 2019 - 2022, USD Million
  • TABLE 86 North America Antiplatelet Market by Country, 2023 - 2030, USD Million
  • TABLE 87 North America Antiplatelet Market by Country, 2019 - 2022, Million Units
  • TABLE 88 North America Antiplatelet Market by Country, 2023 - 2030, Million Units
  • TABLE 89 US Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 90 US Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 91 US Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 92 US Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 93 US Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 94 US Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 95 US Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 96 US Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 97 US Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 98 US Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 99 US Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 100 US Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 101 US Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 102 US Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 103 Canada Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 104 Canada Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 105 Canada Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 106 Canada Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 107 Canada Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 108 Canada Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 109 Canada Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 110 Canada Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 111 Canada Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 112 Canada Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 113 Canada Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 114 Canada Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 115 Canada Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 116 Canada Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 117 Mexico Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 118 Mexico Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 119 Mexico Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 120 Mexico Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 121 Mexico Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 122 Mexico Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 123 Mexico Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 124 Mexico Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 125 Mexico Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 126 Mexico Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 127 Mexico Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 128 Mexico Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 129 Mexico Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 130 Mexico Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 131 Rest of North America Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 132 Rest of North America Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 133 Rest of North America Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 134 Rest of North America Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 135 Rest of North America Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 136 Rest of North America Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 137 Rest of North America Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 138 Rest of North America Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 139 Rest of North America Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 140 Rest of North America Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 141 Rest of North America Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 142 Rest of North America Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 143 Rest of North America Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 144 Rest of North America Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 145 Europe Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 146 Europe Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 147 Europe Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 148 Europe Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 149 Europe Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 150 Europe Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 151 Europe Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 152 Europe Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 153 Europe Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 154 Europe Oral Market by Country, 2023 - 2030, USD Million
  • TABLE 155 Europe Oral (strip of 10) Market by Country, 2019 - 2022, Million Units
  • TABLE 156 Europe Oral (strip of 10) Market by Country, 2023 - 2030, Million Units
  • TABLE 157 Europe Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 158 Europe Injectable Market by Country, 2023 - 2030, USD Million
  • TABLE 159 Europe Injectable Market by Country, 2019 - 2022, Million Units
  • TABLE 160 Europe Injectable Market by Country, 2023 - 2030, Million Units
  • TABLE 161 Europe Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 162 Europe Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 163 Europe Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 164 Europe Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 165 Europe Irreversible Inhibitors Cyclooxygenase Market by Country, 2019 - 2022, USD Million
  • TABLE 166 Europe Irreversible Inhibitors Cyclooxygenase Market by Country, 2023 - 2030, USD Million
  • TABLE 167 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 168 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 169 Europe Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 170 Europe Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 171 Europe Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 172 Europe Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 173 Europe Drug store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 174 Europe Drug store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 175 Europe Drug store & Retail Pharmacies Market by Country, 2019 - 2022, Million Units
  • TABLE 176 Europe Drug store & Retail Pharmacies Market by Country, 2023 - 2030, Million Units
  • TABLE 177 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 178 Europe Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 179 Europe Hospital Pharmacies Market by Country, 2019 - 2022, Million Units
  • TABLE 180 Europe Hospital Pharmacies Market by Country, 2023 - 2030, Million Units
  • TABLE 181 Europe Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 182 Europe Online Providers Market by Country, 2023 - 2030, USD Million
  • TABLE 183 Europe Online Providers Market by Country, 2019 - 2022, Million Units
  • TABLE 184 Europe Online Providers Market by Country, 2023 - 2030, Million Units
  • TABLE 185 Europe Antiplatelet Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Europe Antiplatelet Market by Country, 2023 - 2030, USD Million
  • TABLE 187 Europe Antiplatelet Market by Country, 2019 - 2022, Million Units
  • TABLE 188 Europe Antiplatelet Market by Country, 2023 - 2030, Million Units
  • TABLE 189 Germany Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 190 Germany Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 191 Germany Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 192 Germany Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 193 Germany Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 194 Germany Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 195 Germany Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 196 Germany Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 197 Germany Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 198 Germany Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 199 Germany Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 200 Germany Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 201 Germany Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 202 Germany Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 203 UK Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 204 UK Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 205 UK Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 206 UK Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 207 UK Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 208 UK Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 209 UK Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 210 UK Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 211 UK Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 212 UK Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 213 UK Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 214 UK Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 215 UK Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 216 UK Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 217 France Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 218 France Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 219 France Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 220 France Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 221 France Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 222 France Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 223 France Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 224 France Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 225 France Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 226 France Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 227 France Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 228 France Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 229 France Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 230 France Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 231 Russia Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 232 Russia Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 233 Russia Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 234 Russia Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 235 Russia Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 236 Russia Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 237 Russia Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 238 Russia Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 239 Russia Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 240 Russia Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 241 Russia Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 242 Russia Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 243 Russia Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 244 Russia Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 245 Spain Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 246 Spain Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 247 Spain Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 248 Spain Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 249 Spain Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 250 Spain Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 251 Spain Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 252 Spain Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 253 Spain Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 254 Spain Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 255 Spain Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 256 Spain Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 257 Spain Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 258 Spain Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 259 Italy Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 260 Italy Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 261 Italy Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 262 Italy Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 263 Italy Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 264 Italy Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 265 Italy Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 266 Italy Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 267 Italy Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 268 Italy Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 269 Italy Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 270 Italy Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 271 Italy Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 272 Italy Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
  • TABLE 273 Rest of Europe Antiplatelet Market, 2019 - 2022, USD Million
  • TABLE 274 Rest of Europe Antiplatelet Market, 2023 - 2030, USD Million
  • TABLE 275 Rest of Europe Antiplatelet Market, 2019 - 2022, Million Units
  • TABLE 276 Rest of Europe Antiplatelet Market, 2023 - 2030, Million Units
  • TABLE 277 Rest of Europe Antiplatelet Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 278 Rest of Europe Antiplatelet Market by Route of Administration, 2023 - 2030, USD Million
  • TABLE 279 Rest of Europe Antiplatelet Market by Route of Administration, 2019 - 2022, Million Units
  • TABLE 280 Rest of Europe Antiplatelet Market by Route of Administration, 2023 - 2030, Million Units
  • TABLE 281 Rest of Europe Antiplatelet Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 282 Rest of Europe Antiplatelet Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 283 Rest of Europe Antiplatelet Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 284 Rest of Europe Antiplatelet Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 285 Rest of Europe Antiplatelet Market by Distribution Channel, 2019 - 2022, Million Units
  • TABLE 286 Rest of Europe Antiplatelet Market by Distribution Channel, 2023 - 2030, Million Units
目次

The Global Antiplatelet Market size is expected to reach $5.1 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period. In the year 2022, the market attained a volume of 430.4 million Units experiencing a growth of 3.4 % (2019-2022).

Developing P2Y12 receptor inhibitors, such as clopidogrel, prasugrel, and ticagrelor, marked a significant advancement. The concept of DAPT, which combines aspirin with an ADP receptor inhibitor (e.g., clopidogrel), has become a standard of care in many cardiovascular conditions. Therefore, Adenosine diphosphate (ADP) Receptor Inhibitors segment would generate $2,451.9 million revenue in the market in 2022. As a result, these drugs target the P2Y12 receptor on platelets and are more specific and potent than earlier antiplatelet medications. Research has confirmed the benefits of DAPT in preventing stent thrombosis and reducing the risk of cardiovascular events. Some of the factors impacting the market are increasing prevalence of cardiovascular diseases, rising proportion of aging population and cost and accessibility of antiplatelet.

Lifestyle factors such as sedentary lifestyles, unhealthy diets, smoking, and obesity, as well as non-modifiable risk factors such as genetics and aging, contribute to the development of CVDs. These risk factors are prevalent in many regions, further driving the demand for preventive and therapeutic interventions, including antiplatelet medications. Patients who have already experienced a cardiovascular event, such as a heart attack or stroke, require long-term antiplatelet therapy to reduce the risk of recurrent events. The growing number of individuals with a history of CVD contributes to sustained demand for antiplatelet drugs. Additionally, the global population is aging, and elderly individuals are at a higher risk of CVD. As the elderly population grows, the need for antiplatelet medications to manage and prevent heart and vascular conditions increases. Aging is a significant risk factor for cardiovascular diseases (CVDs). Older individuals are more likely to develop coronary artery disease, stroke, and peripheral artery disease. As the population ages, the incidence of these conditions rises, leading to an increased demand for antiplatelet therapy to manage and prevent CVDs. Therefore, the increasing prevalence of cardiovascular diseases is one of the most significant drivers of the market and the aging population is a substantial demographic trend that profoundly impacts the market.

However, access to healthcare and medications, including antiplatelet therapy, varies significantly between high-income and low-income countries. Disparities in healthcare infrastructure and resources can limit access to essential medications in underserved regions. Patients in rural or remote areas face challenges accessing healthcare facilities and pharmacies where antiplatelet medications are available. Geographic barriers can lead to delays in treatment. Periodic shortages of certain medications, including antiplatelet drugs, can disrupt patient care and lead to difficulty obtaining essential medications. Cost and accessibility challenges are significant barriers that affect the market and can impact patients' access to essential medications.

Additionally, numerous nations' healthcare systems were significantly focused on addressing the immediate threats posed by COVID-19. This shift in priorities led to disruptions in routine healthcare services, including managing chronic conditions like cardiovascular diseases. As a result, some patients experienced delays in receiving antiplatelet therapy or regular check-ups. During the pandemic, there was a shift in prescription patterns. Some healthcare providers altered treatment plans to reduce the need for in-person visits and laboratory monitoring. This led to changes in the choice of antiplatelet drugs or dosage adjustments. Furthermore, the increase in demand for parenteral antiplatelet drugs during the pandemic positively impacted the market's growth.

Route of Administration Outlook

Based on route of administration, the market is classified into oral and injectable. In 2022, the oral segment witnessed the largest revenue share in the market. Aspirin is one of the oldest and most widely used oral antiplatelet medications. It works by irreversibly inhibiting cyclooxygenase-1 (COX-1), which reduces the production of thromboxane A2 (TXA2), a platelet aggregator. Aspirin is often used in low doses to prevent cardiovascular events like heart attacks and strokes. Oral antiplatelet medications are a significant component of the antiplatelet market. These medications are taken by mouth to inhibit platelet aggregation, reduce the risk of blood clot formation, and prevent or manage various cardiovascular conditions.

Drug Class Outlook

By drug class, the market is categorized into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. The irreversible inhibitors cyclooxygenase segment covered a considerable revenue share in the market in 2022. Irreversible COX inhibitors like aspirin often combine with ADP receptor inhibitors (like clopidogrel) to provide dual antiplatelet therapy (DAPT). DAPT is commonly prescribed after coronary stent placement and in patients with acute coronary syndrome (ACS) to prevent blood clot formation and lower the risk of cardiovascular events.

Distribution Channel Outlook

On the basis of distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies, and online providers. The drug store and retail pharmacies segment dominated the market with maximum revenue share in 2022. Local communities ' drug stores and retail pharmacies ensure that a wide range of antiplatelet medications, including over-the-counter aspirin and prescription drugs like clopidogrel, ticagrelor, and others, are readily available to patients. This increased accessibility is crucial for both acute and chronic conditions. The expansion of drug store and retail pharmacies enhances patient access and contributes to medication safety, education, and adherence.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. North America has a high prevalence of cardiovascular diseases, including stroke, coronary artery disease, and peripheral artery disease. These conditions often require antiplatelet therapy to reduce the risk of thrombotic events like heart attacks and strokes. A wide range of antiplatelet drugs is available in North America, including aspirin, clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and others. These drugs are used for various indications, such as acute coronary syndrome, post-stent placement, and secondary prevention.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration (Volume, Million Units, USD Million, 2019-2030)

  • Oral
  • Injectable

By Drug Class (Volume, Million Units, USD Million, 2019-2030)

  • Adenosine diphosphate (ADP) Receptor Inhibitors
  • Irreversible Inhibitors Cyclooxygenase
  • Others

By Distribution Channel (Volume, Million Units, USD Million, 2019-2030)

  • Drug store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Geography (Volume, Million Units, USD Million, 2019-2030)

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Eli Lilly And Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Lupin Limited
  • Chiesi Farmaceutici S.p.A

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Antiplatelet Market, by Route of Administration
    • 1.4.2 Global Antiplatelet Market, by Drug Class
    • 1.4.3 Global Antiplatelet Market, by Distribution Channel
    • 1.4.4 Global Antiplatelet Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market At a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
  • 3.3 Porter's Five Force Analysis

Chapter 4. Global Antiplatelet Market by Route of Administration

  • 4.1 Global Oral Market by Region
  • 4.2 Global Injectable Market by Region

Chapter 5. Global Antiplatelet Market by Drug Class

  • 5.1 Global Adenosine diphosphate (ADP) Receptor Inhibitors Market by Region
  • 5.2 Global Irreversible Inhibitors Cyclooxygenase Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global Antiplatelet Market by Distribution Channel

  • 6.1 Global Drug store & Retail Pharmacies Market by Region
  • 6.2 Global Hospital Pharmacies Market by Region
  • 6.3 Global Online Providers Market by Region

Chapter 7. Global Antiplatelet Market by Region

  • 7.1 North America Antiplatelet Market
    • 7.1.1 North America Antiplatelet Market by Route of Administration
      • 7.1.1.1 North America Oral Market by Country
      • 7.1.1.2 North America Injectable Market by Country
    • 7.1.2 North America Antiplatelet Market by Drug Class
      • 7.1.2.1 North America Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country
      • 7.1.2.2 North America Irreversible Inhibitors Cyclooxygenase Market by Country
      • 7.1.2.3 North America Others Market by Country
    • 7.1.3 North America Antiplatelet Market by Distribution Channel
      • 7.1.3.1 North America Drug store & Retail Pharmacies Market by Country
      • 7.1.3.2 North America Hospital Pharmacies Market by Country
      • 7.1.3.3 North America Online Providers Market by Country
    • 7.1.4 North America Antiplatelet Market by Country
      • 7.1.4.1 US Antiplatelet Market
        • 7.1.4.1.1 US Antiplatelet Market by Route of Administration
        • 7.1.4.1.2 US Antiplatelet Market by Drug Class
        • 7.1.4.1.3 US Antiplatelet Market by Distribution Channel
      • 7.1.4.2 Canada Antiplatelet Market
        • 7.1.4.2.1 Canada Antiplatelet Market by Route of Administration
        • 7.1.4.2.2 Canada Antiplatelet Market by Drug Class
        • 7.1.4.2.3 Canada Antiplatelet Market by Distribution Channel
      • 7.1.4.3 Mexico Antiplatelet Market
        • 7.1.4.3.1 Mexico Antiplatelet Market by Route of Administration
        • 7.1.4.3.2 Mexico Antiplatelet Market by Drug Class
        • 7.1.4.3.3 Mexico Antiplatelet Market by Distribution Channel
      • 7.1.4.4 Rest of North America Antiplatelet Market
        • 7.1.4.4.1 Rest of North America Antiplatelet Market by Route of Administration
        • 7.1.4.4.2 Rest of North America Antiplatelet Market by Drug Class
        • 7.1.4.4.3 Rest of North America Antiplatelet Market by Distribution Channel
  • 7.2 Europe Antiplatelet Market
    • 7.2.1 Europe Antiplatelet Market by Route of Administration
      • 7.2.1.1 Europe Oral Market by Country
      • 7.2.1.2 Europe Injectable Market by Country
    • 7.2.2 Europe Antiplatelet Market by Drug Class
      • 7.2.2.1 Europe Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country
      • 7.2.2.2 Europe Irreversible Inhibitors Cyclooxygenase Market by Country
      • 7.2.2.3 Europe Others Market by Country
    • 7.2.3 Europe Antiplatelet Market by Distribution Channel
      • 7.2.3.1 Europe Drug store & Retail Pharmacies Market by Country
      • 7.2.3.2 Europe Hospital Pharmacies Market by Country
      • 7.2.3.3 Europe Online Providers Market by Country
    • 7.2.4 Europe Antiplatelet Market by Country
      • 7.2.4.1 Germany Antiplatelet Market
        • 7.2.4.1.1 Germany Antiplatelet Market by Route of Administration
        • 7.2.4.1.2 Germany Antiplatelet Market by Drug Class
        • 7.2.4.1.3 Germany Antiplatelet Market by Distribution Channel
      • 7.2.4.2 UK Antiplatelet Market
        • 7.2.4.2.1 UK Antiplatelet Market by Route of Administration
        • 7.2.4.2.2 UK Antiplatelet Market by Drug Class
        • 7.2.4.2.3 UK Antiplatelet Market by Distribution Channel
      • 7.2.4.3 France Antiplatelet Market
        • 7.2.4.3.1 France Antiplatelet Market by Route of Administration
        • 7.2.4.3.2 France Antiplatelet Market by Drug Class
        • 7.2.4.3.3 France Antiplatelet Market by Distribution Channel
      • 7.2.4.4 Russia Antiplatelet Market
        • 7.2.4.4.1 Russia Antiplatelet Market by Route of Administration
        • 7.2.4.4.2 Russia Antiplatelet Market by Drug Class
        • 7.2.4.4.3 Russia Antiplatelet Market by Distribution Channel
      • 7.2.4.5 Spain Antiplatelet Market
        • 7.2.4.5.1 Spain Antiplatelet Market by Route of Administration
        • 7.2.4.5.2 Spain Antiplatelet Market by Drug Class
        • 7.2.4.5.3 Spain Antiplatelet Market by Distribution Channel
      • 7.2.4.6 Italy Antiplatelet Market
        • 7.2.4.6.1 Italy Antiplatelet Market by Route of Administration
        • 7.2.4.6.2 Italy Antiplatelet Market by Drug Class
        • 7.2.4.6.3 Italy Antiplatelet Market by Distribution Channel
      • 7.2.4.7 Rest of Europe Antiplatelet Market
        • 7.2.4.7.1 Rest of Europe Antiplatelet Market by Route of Administration
        • 7.2.4.7.2 Rest of Europe Antiplatelet Market by Drug Class
        • 7.2.4.7.3 Rest of Europe Antiplatelet Market by Distribution Channel
  • 7.3 Asia Pacific Antiplatelet Market
    • 7.3.1 Asia Pacific Antiplatelet Market by Route of Administration
      • 7.3.1.1 Asia Pacific Oral Market by Country
      • 7.3.1.2 Asia Pacific Injectable Market by Country
    • 7.3.2 Asia Pacific Antiplatelet Market by Drug Class
      • 7.3.2.1 Asia Pacific Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country
      • 7.3.2.2 Asia Pacific Irreversible Inhibitors Cyclooxygenase Market by Country
      • 7.3.2.3 Asia Pacific Others Market by Country
    • 7.3.3 Asia Pacific Antiplatelet Market by Distribution Channel
      • 7.3.3.1 Asia Pacific Drug store & Retail Pharmacies Market by Country
      • 7.3.3.2 Asia Pacific Hospital Pharmacies Market by Country
      • 7.3.3.3 Asia Pacific Online Providers Market by Country
    • 7.3.4 Asia Pacific Antiplatelet Market by Country
      • 7.3.4.1 China Antiplatelet Market
        • 7.3.4.1.1 China Antiplatelet Market by Route of Administration
        • 7.3.4.1.2 China Antiplatelet Market by Drug Class
        • 7.3.4.1.3 China Antiplatelet Market by Distribution Channel
      • 7.3.4.2 Japan Antiplatelet Market
        • 7.3.4.2.1 Japan Antiplatelet Market by Route of Administration
        • 7.3.4.2.2 Japan Antiplatelet Market by Drug Class
        • 7.3.4.2.3 Japan Antiplatelet Market by Distribution Channel
      • 7.3.4.3 India Antiplatelet Market
        • 7.3.4.3.1 India Antiplatelet Market by Route of Administration
        • 7.3.4.3.2 India Antiplatelet Market by Drug Class
        • 7.3.4.3.3 India Antiplatelet Market by Distribution Channel
      • 7.3.4.4 South Korea Antiplatelet Market
        • 7.3.4.4.1 South Korea Antiplatelet Market by Route of Administration
        • 7.3.4.4.2 South Korea Antiplatelet Market by Drug Class
        • 7.3.4.4.3 South Korea Antiplatelet Market by Distribution Channel
      • 7.3.4.5 Singapore Antiplatelet Market
        • 7.3.4.5.1 Singapore Antiplatelet Market by Route of Administration
        • 7.3.4.5.2 Singapore Antiplatelet Market by Drug Class
        • 7.3.4.5.3 Singapore Antiplatelet Market by Distribution Channel
      • 7.3.4.6 Malaysia Antiplatelet Market
        • 7.3.4.6.1 Malaysia Antiplatelet Market by Route of Administration
        • 7.3.4.6.2 Malaysia Antiplatelet Market by Drug Class
        • 7.3.4.6.3 Malaysia Antiplatelet Market by Distribution Channel
      • 7.3.4.7 Rest of Asia Pacific Antiplatelet Market
        • 7.3.4.7.1 Rest of Asia Pacific Antiplatelet Market by Route of Administration
        • 7.3.4.7.2 Rest of Asia Pacific Antiplatelet Market by Drug Class
        • 7.3.4.7.3 Rest of Asia Pacific Antiplatelet Market by Distribution Channel
  • 7.4 LAMEA Antiplatelet Market
    • 7.4.1 LAMEA Antiplatelet Market by Route of Administration
      • 7.4.1.1 LAMEA Oral Market by Country
      • 7.4.1.2 LAMEA Injectable Market by Country
    • 7.4.2 LAMEA Antiplatelet Market by Drug Class
      • 7.4.2.1 LAMEA Adenosine diphosphate (ADP) Receptor Inhibitors Market by Country
      • 7.4.2.2 LAMEA Irreversible Inhibitors Cyclooxygenase Market by Country
      • 7.4.2.3 LAMEA Others Market by Country
    • 7.4.3 LAMEA Antiplatelet Market by Distribution Channel
      • 7.4.3.1 LAMEA Drug store & Retail Pharmacies Market by Country
      • 7.4.3.2 LAMEA Hospital Pharmacies Market by Country
      • 7.4.3.3 LAMEA Online Providers Market by Country
    • 7.4.4 LAMEA Antiplatelet Market by Country
      • 7.4.4.1 Brazil Antiplatelet Market
        • 7.4.4.1.1 Brazil Antiplatelet Market by Route of Administration
        • 7.4.4.1.2 Brazil Antiplatelet Market by Drug Class
        • 7.4.4.1.3 Brazil Antiplatelet Market by Distribution Channel
      • 7.4.4.2 Argentina Antiplatelet Market
        • 7.4.4.2.1 Argentina Antiplatelet Market by Route of Administration
        • 7.4.4.2.2 Argentina Antiplatelet Market by Drug Class
        • 7.4.4.2.3 Argentina Antiplatelet Market by Distribution Channel
      • 7.4.4.3 UAE Antiplatelet Market
        • 7.4.4.3.1 UAE Antiplatelet Market by Route of Administration
        • 7.4.4.3.2 UAE Antiplatelet Market by Drug Class
        • 7.4.4.3.3 UAE Antiplatelet Market by Distribution Channel
      • 7.4.4.4 Saudi Arabia Antiplatelet Market
        • 7.4.4.4.1 Saudi Arabia Antiplatelet Market by Route of Administration
        • 7.4.4.4.2 Saudi Arabia Antiplatelet Market by Drug Class
        • 7.4.4.4.3 Saudi Arabia Antiplatelet Market by Distribution Channel
      • 7.4.4.5 South Africa Antiplatelet Market
        • 7.4.4.5.1 South Africa Antiplatelet Market by Route of Administration
        • 7.4.4.5.2 South Africa Antiplatelet Market by Drug Class
        • 7.4.4.5.3 South Africa Antiplatelet Market by Distribution Channel
      • 7.4.4.6 Nigeria Antiplatelet Market
        • 7.4.4.6.1 Nigeria Antiplatelet Market by Route of Administration
        • 7.4.4.6.2 Nigeria Antiplatelet Market by Drug Class
        • 7.4.4.6.3 Nigeria Antiplatelet Market by Distribution Channel
      • 7.4.4.7 Rest of LAMEA Antiplatelet Market
        • 7.4.4.7.1 Rest of LAMEA Antiplatelet Market by Route of Administration
        • 7.4.4.7.2 Rest of LAMEA Antiplatelet Market by Drug Class
        • 7.4.4.7.3 Rest of LAMEA Antiplatelet Market by Distribution Channel

Chapter 8. Company Profiles

  • 8.1 Cipla Limited
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
    • 8.1.5 SWOT Analysis
  • 8.2 Glenmark Pharmaceuticals Limited
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Regional Analysis
    • 8.2.4 Research & Development Expenses
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Approvals:
    • 8.2.6 SWOT Analysis
  • 8.3 Bayer AG
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 SWOT Analysis
  • 8.4 AstraZeneca PLC
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 SWOT Analysis
  • 8.5 Daiichi Sankyo Company, Limited
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Product and Services and Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
    • 8.5.6 SWOT Analysis
  • 8.6 Eli Lilly And Company
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 SWOT Analysis
  • 8.7 Otsuka Pharmaceutical Co., Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental and Regional Analysis
    • 8.7.4 Research & Development Expense
    • 8.7.5 SWOT Analysis
  • 8.8 Sanofi S.A.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 SWOT Analysis
  • 8.9 Lupin Limited
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expense
    • 8.9.5 SWOT Analysis
  • 8.10. Chiesi Farmaceutici S.p.A
    • 8.10.1 Company Overview
    • 8.10.2 SWOT Analysis

Chapter 9. Winning imperative of Antiplatelet Market